Clinical Trial Update: A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for pridopidine (ACR16) in Huntington's Disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• pridopidine (ACR16) (pridopidine)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Huntington's Disease | Phase 3 | Status: COMPLETED | Results posted: 2023-08-29